Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Emerging drugs for hemophilia A: insights into phase II and III clinical trials27
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder25
Emerging drugs for the treatment of postsurgical pain22
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?20
New drugs targeting calcitonin gene-related peptide for the management of migraines18
A review of phase II and III drugs for the treatment and management of endometriosis16
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review15
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials15
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia15
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials14
Emerging medicines to improve the basic defect in cystic fibrosis14
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?12
Emerging biological treatments for asthma11
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia11
Emerging injectable therapies for osteoarthritis10
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials10
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials9
A review of emerging factor XI inhibitors9
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms9
Emerging tyrosine kinase inhibitors for head and neck cancer7
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma7
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?7
Emerging drugs for the treatment of herpetic keratitis7
Recent advances in immune-based approaches for the treatment of esophagogastric cancer7
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder7
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria7
Cannabinoid treatment for the symptoms of autism spectrum disorder7
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma7
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials7
Expert opinion on emerging drugs for lung chronic graft-versus-host disease7
Emerging drugs for the treatment of irritability associated with autism spectrum disorder6
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion6
Correction6
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis6
Emerging antiviral therapies and drugs for the treatment of influenza6
Emerging therapies for dry eye disease6
Resiquimod: a new topical immune-response modifier for the treatment of actinic keratosis6
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials6
How will tovorafenib change our treatment of pediatric low-grade glioma?6
The role of HER2-targeted therapy in urothelial carcinomas5
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma5
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis5
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?5
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials5
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results5
An update on emerging drugs for the treatment of hypercholesterolemia5
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials5
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials5
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis5
Emerging drugs for the treatment of inflammatory bowel disease5
Correction5
Emerging drugs in the treatment of chronic cough4
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma4
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma4
Current and emerging drug treatment strategies to tackle sickle cell anemia4
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma4
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia4
Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency4
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa4
What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II4
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond3
Emerging drugs for the treatment of alopecia areata3
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E3
Emerging drugs for the treatment of diabetic nephropathy3
Emerging drugs for the treatment of major depressive disorder3
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’3
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis3
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder3
Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials3
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials3
0.084397077560425